|
1
|
Hoffman D and Mehta N: Recurrence of
hepatocellular carcinoma following liver transplantation. Expert
Rev Gastroenterol Hepatol. 15:91–102. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Al-Joundi T, Gibson S, Brunt EM, Shakil O,
Lee RS and Di Bisceglie AM: Delayed recurrence of hepatocellular
carcinoma after liver transplantation: Detection of origin by
chromosomal analysis. Liver Transpl. 6:374–375. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allaire M and Nault JC. Type 2
diabetes-associated hepatocellular carcinoma: A molecular profile.
Clin Liver Dis (Hoboken). 8:53–58. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Croitoru A, Schiano TD, Schwartz M,
Roayaie S, Xu R, Suriawinata A and Fiel MI: De novo hepatocellular
carcinoma occurring in a transplanted liver: Case report and review
of the literature. Dig Dis Sci. 51:1780–1782. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
El-Domiaty N, Saliba F, Sebagh M, Salloum
C, Vibert E, Azoulay D, Hamelin J, Cherqui D, Adam R and Samuel D:
De novo hepatocellular carcinoma in a non-cirrhotic allograft 27
years after liver transplantation: A case report. Am J Transplant.
21:1953–1958. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Flemming P, Tillmann HL, Barg-Hock H,
Kleeberger W, Manns MP, Klempnauer J and Kreipe HH: Donor origin of
de novo hepatocellular carcinoma in hepatic allografts.
Transplantation. 76:1625–1627. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kita Y, Klintmalm G, Kobayashi S and
Yanaga K: Retransplantation for de novo hepatocellular carcinoma in
a liver allograft with recurrent hepatitis B cirrhosis 14 years
after primary liver transplantation. Dig Dis Sci. 52:3392–3393.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Levitsky J, Faust TW, Cohen SM and Te HS:
Group G streptococcal bacteremia and de novo hepatocellular
carcinoma after liver transplantation. Liver Transpl. 8:5722002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morita K, Taketomi A, Soejima Y, Ikegami
T, Fukuhara T, Iguchi T, Nagata S, Sugimachi K, Gion T, Shirabe K
and Maehara Y: De novo hepatocellular carcinoma in a liver graft
with sustained hepatitis C virus clearance after living donor liver
transplantation. Liver Transpl. 15:1412–1416. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Navarro Burgos JB, Lee KW, Shin YC, Lee
DS, Lee KB, Yi NJ and Suh KS: Inexplicable outcome of early
appearance of hepatocellular carcinoma in the allograft after
deceased donor liver transplantation: A case report. Transplant
Proc. 47:3012–3015. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ramadori G, Bosio P, Moriconi F and Malik
IA: Case report: 8 years after liver transplantation: De novo
hepatocellular carcinoma 8 months after HCV clearance through
IFN-free antiviral therapy. BMC Cancer. 18:2572018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saab S, Zhou K, Chang EK and Busuttil RW:
De novo Hepatocellular Carcinoma after Liver Transplantation. J
Clin Transl Hepatol. 3:284–287. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saxena R, Ye MQ, Emre S, Klion F, Nalesnik
MA and Thung SN: De novo hepatocellular carcinoma in a hepatic
allograft with recurrent hepatitis C cirrhosis. Liver Transpl Surg.
5:81–82. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sotiropoulos GC, Frilling A, Molmenti EP,
Brokalaki EI, Beckebaum S, Omar OS, Broelsch CE and Malagó M: De
novo hepatocellular carcinoma in recurrent liver cirrhosis after
liver transplantation for benign hepatic disease: Is a deceased
donor re-transplantation justified? Transplantation. 82:11122006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Torbenson M, Grover D, Boitnott J, Klein A
and Molmenti E: De novo hepatocellular carcinoma in a liver
allograft associated with recurrent hepatitis B. Transplant Proc.
37:2205–2206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu S, Guo H, Zhuang L, Yu J, Yan S, Zhang
M, Wang W and Zheng S: A case report of de novo hepatocellular
carcinoma after living donor liver transplantation. World J Surg
Oncol. 11:1762013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoo JJ, Cho EJ, Han K, Heo SS, Kim BY,
Shin DW and Yu SJ: Glucose variability and risk of hepatocellular
carcinoma in patients with diabetes: A nationwide population-based
study. Cancer Epidemiol Biomarkers Prev. 30:974–981. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tame M, Calvanese C, Cucchetti A,
Gruppioni E, Colecchia A and Bazzoli F: The onset of de novo
hepatocellular carcinoma after liver transplantation can be both of
donor and recipient origin. A case report. J Gastrointestin Liver
Dis. 24:387–389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Allaire M, Seree O, Coilly A,
Houssel-Debry P, Neau-Cransac M, Pageaux GP, Dumortier J and
Altieri M: De novo primary liver cancer after liver
transplantation: A French National Study on 15803 Patients. Exp
Clin Transplant. 16:779–780. 2018.PubMed/NCBI
|
|
20
|
Vajdic CM and van Leeuwen MT: Cancer
incidence and risk factors after solid organ transplantation. Int J
Cancer. 125:1747–1754. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Giovannucci E, Harlan DM, Archer MC,
Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and
Yee D: Diabetes and cancer: A consensus report. Diabetes Care.
33:1674–1685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hung CH, Wang JH, Hu TH, Chen CH, Chang
KC, Yen YH, Kuo YH, Tsai MC, Lu SN and Lee CM: Insulin resistance
is associated with hepatocellular carcinoma in chronic hepatitis C
infection. World J Gastroenterol. 16:2265–2271. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Inoue M, Iwasaki M, Otani T, Sasazuki S,
Noda M and Tsugane S: Diabetes mellitus and the risk of cancer:
Results from a large-scale population-based cohort study in Japan.
Arch Intern Med. 166:1871–1877. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin CM, Huang HL, Chu FY, Fan HC, Chen HA,
Chu DM, Wu LW, Wang CC, Chen WL, Lin SH and Ho SY: Association
between gastroenterological malignancy and diabetes mellitus and
anti-diabetic therapy: A nationwide, population-based cohort study.
PLoS One. 10:e01254212015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mantovani A and Targher G: Type 2 diabetes
mellitus and risk of hepatocellular carcinoma: Spotlight on
nonalcoholic fatty liver disease. Ann Transl Med. 5:2702017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van Kruijsdijk RC, van der Wall E and
Visseren FL: Obesity and cancer: The role of dysfunctional adipose
tissue. Cancer Epidemiol Biomarkers Prev. 18:2569–2578. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen
Y, Li G and Wang L: Increased risk of hepatocellular carcinoma in
patients with diabetes mellitus: A systematic review and
meta-analysis of cohort studies. Int J Cancer. 130:1639–1648. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wojciechowska J, Krajewski W, Bolanowski
M, Krecicki T and Zatonski T: Diabetes and Cancer: A Review of
Current Knowledge. Exp Clin Endocrinol Diabetes. 124:263–275. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang H, Pelzer AM, Kiang DT and Yee D:
Down-regulation of type I insulin-like growth factor receptor
increases sensitivity of breast cancer cells to insulin. Cancer
Res. 67:391–397. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Macdonald GA, Greenson JK, Saito K,
Cherian SP, Appelman HD and Boland CR: Microsatellite instability
and loss of heterozygosity at DNA mismatch repair gene loci occurs
during hepatic carcinogenesis. Hepatology. 28:90–97. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matsukura S, Soejima H, Nakagawachi T,
Yakushiji H, Ogawa A, Fukuhara M, Miyazaki K, Nakabeppu Y,
Sekiguchi M and Mukai T: CpG methylation of MGMT and hMLH1 promoter
in hepatocellular carcinoma associated with hepatitis viral
infection. Br J Cancer. 88:521–529. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Suriawinata A and Xu R: An update on the
molecular genetics of hepatocellular carcinoma. Semin Liver Dis.
24:77–88. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thorgeirsson SS and Grisham JW: Molecular
pathogenesis of human hepatocellular carcinoma. Nat Genet.
31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang SH, Cong WM, Xian ZH and Wu MC:
Clinicopathological significance of loss of heterozygosity and
microsatellite instability in hepatocellular carcinoma in China.
World J Gastroenterol. 11:3034–3039. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brierly JD, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. Eighth Edition.
Whiley-Blackwell; Hoboken, N, USA: pp. 73–76. 2017
|
|
36
|
Morikawa T, Yamamoto Y and Miyaishi S: A
new method for sex determination based on detection of SRY, STS and
amelogenin gene regions with simultaneous amplification of their
homologous sequences by a multiplex PCR. Acta Med Okayama.
65:113–122. 2011.PubMed/NCBI
|
|
37
|
Wang LJ, Chen YM, George D, Smets F, Sokal
EM, Bremer EG and Soriano HE: Engraftment assessment in human and
mouse liver tissue after sex-mismatched liver cell transplantation
by real-time quantitative PCR for Y chromosome sequences. Liver
Transpl. 8:822–828. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sakuraoka Y, Kubota K, Imura J, Yamagishi
H, Aoki T, Matsumoto T, Arakawa T, Suzuki T, Tanaka G, Shimizu T,
et al: Microsatellite analysis of recurrent lesions confirms merit
of anatomical liver resection for hepatocellular carcinoma.
Anticancer Res. 39:4315–4324. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhong Y, Han J, Zou Z, Liu S, Tang B, Ren
X, Li X, Zhao Y, Liu Y, Zhou D, et al: Quantitation of HBV
covalently closed circular DNA in micro formalin fixed
paraffin-embedded liver tissue using rolling circle amplification
in combination with real-time PCR. Clin Chim Acta. 412:1905–1911.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Helal TE, Khamis NS, El-Sharkawy TM, Nada
OH and Radwan NA: Immunohistochemical expression of mismatch repair
genes (hMSH2 and hMLH1) in hepatocellular carcinoma in Egypt.
APMIS. 118:934–940. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Feitelson MA, Sun B, Satiroglu Tufan NL,
Liu J, Pan J and Lian Z: Genetic mechanisms of
hepatocarcinogenesis. Oncogene. 21:2593–2604. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Frey AB and Monu N: Signaling defects in
anti-tumor T cells. Immunol Rev. 222:192–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Maluccio M, Sharma V, Lagman M, Vyas S,
Yang H, Li B and Suthanthiran M: Tacrolimus enhances transforming
growth factor-beta1 expression and promotes tumor progression.
Transplantation. 76:597–602. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Giovannucci E: Insulin, insulin-like
growth factors and colon cancer: A review of the evidence. J Nutr.
131 (11 Suppl):3109S–3120S. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Azhie A, Sheth P, Hammad A, Woo M and Bhat
M: Metabolic complications in liver transplantation recipients: How
we can optimize long-term survival. Liver Transpl. 27:1468–1478.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Seow A, Yuan JM, Koh WP, Lee HP and Yu MC:
Diabetes mellitus and risk of colorectal cancer in the Singapore
Chinese Health Study. J Natl Cancer Inst. 98:135–138. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Roudko V, Cimen Bozkus C, Greenbaum B,
Lucas A, Samstein R and Bhardwaj N: Lynch Syndrome and MSI-H
Cancers: From mechanisms to ‘Off-The-Shelf’ cancer vaccines. Front
Immunol. 12:7578042021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang L, Bani-Hani A, Montoya DP, Roche PC,
Thibodeau SN, Burgart LJ and Roberts LR: hMLH1 and hMSH2 expression
in human hepatocellular carcinoma. Int J Oncol. 19:567–570.
2001.PubMed/NCBI
|
|
50
|
Wani Y, Notohara K, Tsukayama C and Okada
S: Reduced expression of hMLH1 and hMSH2 gene products in
high-grade hepatocellular carcinoma. Acta Med Okayama. 55:65–71.
2001.PubMed/NCBI
|
|
51
|
Marcus VA, Madlensky L, Gryfe R, Kim H, So
K, Millar A, Temple LK, Hsieh E, Hiruki T, Narod S, et al:
Immunohistochemistry for hMLH1 and hMSH2: A practical test for DNA
mismatch repair-deficient tumors. Am J Surg Pathol. 23:1248–1255.
1999. View Article : Google Scholar : PubMed/NCBI
|
